E Fund Management Co. Ltd. acquired a new position in Chimerix, Inc. (NASDAQ:CMRX) in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 5,326 shares of the biopharmaceutical company’s stock, valued at approximately $51,000.
A number of other institutional investors have also added to or reduced their stakes in CMRX. BlackRock Inc. lifted its stake in Chimerix by 18.3% in the first quarter. BlackRock Inc. now owns 4,561,473 shares of the biopharmaceutical company’s stock valued at $43,972,000 after buying an additional 706,656 shares during the last quarter. UBS Group AG lifted its stake in Chimerix by 2,934.9% in the first quarter. UBS Group AG now owns 299,273 shares of the biopharmaceutical company’s stock valued at $2,885,000 after buying an additional 289,412 shares during the last quarter. Russell Investments Group Ltd. lifted its stake in Chimerix by 320.5% in the first quarter. Russell Investments Group Ltd. now owns 234,599 shares of the biopharmaceutical company’s stock valued at $2,260,000 after buying an additional 178,809 shares during the last quarter. Rafferty Asset Management LLC bought a new stake in Chimerix in the first quarter valued at $1,234,000. Finally, Opaleye Management Inc. lifted its stake in Chimerix by 3.0% in the fourth quarter. Opaleye Management Inc. now owns 3,956,500 shares of the biopharmaceutical company’s stock valued at $19,110,000 after buying an additional 115,000 shares during the last quarter. 55.88% of the stock is owned by hedge funds and other institutional investors.
A number of equities research analysts have issued reports on CMRX shares. Jonestrading reiterated a “buy” rating and issued a $14.00 target price on shares of Chimerix in a research note on Monday, April 12th. Wedbush initiated coverage on shares of Chimerix in a research note on Wednesday, March 31st. They set an “outperform” rating and a $21.00 price objective on the stock. Zacks Investment Research cut shares of Chimerix from a “buy” rating to a “hold” rating in a research note on Wednesday, June 2nd. HC Wainwright lifted their price objective on shares of Chimerix from $18.00 to $19.00 and gave the company a “buy” rating in a research note on Monday. Finally, Jefferies Financial Group initiated coverage on shares of Chimerix in a research note on Wednesday, March 31st. They set a “buy” rating and a $21.00 price objective on the stock. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $17.38.
Chimerix (NASDAQ:CMRX) last issued its quarterly earnings results on Thursday, May 6th. The biopharmaceutical company reported ($1.21) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.73). Chimerix had a negative return on equity of 49.70% and a negative net margin of 2,344.90%. The business had revenue of $1.44 million during the quarter. As a group, equities analysts anticipate that Chimerix, Inc. will post -0.08 EPS for the current fiscal year.
Chimerix, Inc, a development-stage biopharmaceutical company, focuses on accelerating the advancement of various medicines that impact in the lives of patients living with cancer and other serious diseases. Its clinical stage development programs include brincidofovir (BCV), an antiviral drug candidate in development as a medical countermeasure for smallpox; dociparstat sodium (DSTAT), which inhibits the activities of key proteins implicated in the resistance of acute myeloid leukemia blasts and leukemic stem cells to chemotherapy; and ONC201 a program for potentially treating tumors which harbor the H3 K27M mutation in recurrent diffuse midline glioma patients.
Recommended Story: What is a stock portfolio tracker?
Receive News & Ratings for Chimerix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix and related companies with MarketBeat.com's FREE daily email newsletter.